NewsRelease
HemoglobinRemoval Whitepaper Describes a Range of Depletion Strategies andTheir Successful Uses
MONMOUTHJUNCTION, NJ, May8, 2020 -- Biotech Support Group reports on a Whitepaper describingthe simplicity and efficiency of their hemoglobin depletiontechnology in a diverse range of applications including theannotationof the redcell proteome, the identification of drug-target interactions, andthe removal of a variety of analytical interferences.
TheWhitepaper is entitled:
“HemoglobinRemoval - The Gold Standard Products”,April 28, 2020
Hemoglobinaccounts for ≥ 95% of the protein mass in erythrocytes, and isoften an interfering factor for many types of analysis, bothproteinaceous (i.e., immunoassay) and non-proteinaceous (i.e., PCR).With the rising use of dried blood cards and point-of-care devices,analytical interferences from Hemoglobin continues to presentproblems. BSG products offer a simple and efficient solution forHemoglobin removal in a variety of separation strategies and formats.Out of the 40+ citations for these products, the Whitepaperhighlights some of the more definitive examples of how Hemoglobindepletion improved the value of the research investigation.Successful uses are described for diseases such as Malaria andParkinson's Disease, as well as drug-target interactions andpost-translational modifications discovered from erythrocyteproteomes. Sample types include erythrocyte lysates, hemolyzed serum,whole blood, and dried blood cards. The BSG application specificproducts are especially designed for all these challenges.
“Wenow know that red cells carry more than just oxygen, and cooperate insome way with the other blood compartments. With the efficiency ofHemoglobin removal that our products provide, investigators can nowstudy the many aspects of red cells as they relate to disease.Finally, we can provide a simple method to remove Hemoglobininterference, as this can often be a problem with more routineclinical analysis. This is becoming especially important with thegrowing use of dried blood cards and point-of-care devices”, statesSwapan Roy, Ph.D., President and Founder of Biotech Support Group.
Formore information on all of our Hemoglobin removal products, visit:https://www.biotechsupportgroup.com/Articles.asp?ID=452
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, and HemogloBind™ and HemoVoid™ for hemoglobinremoval. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, go tohttp://www.biotechsupportgroup.com
ForBusiness Development, Contact:
MatthewKuruc 732-274-2866, [email protected]